https://www.selleckchem.com/pr....oducts/Decitabine.ht
6%), myocardial infarction (1.6%), lower limb ischemia (1.6%). A reintervention was required in six patients (9.8%). The false lumen thrombosis rates were 91.8% (45/49) at 1-year follow-up. One patient died during follow-up from an aneurysm-related cause. The estimated overall survival rates were 98.4%, 96.8% at 6 and 12 months, respectively. The report confirmed the feasibility and safety of F/B-EVAR in the setting of post-dissection TAAAs. Despite the associated perioperative risk and high probability of intended or unintended rein
Like
Comment
Share
